Revance Therapeutics Inc (RVNC)

[iwfal]

The bearish item is 2024-2025 guidance,

I’d suggest the below (related) quote, from the presentation, is equivalently bearish since q3 US aesthetics retreat vs q2 is only about 15-20%, so seasonally adjusted Daxxy grew only about 20% (not what you might expect from a ‘best in class’ product in their first year of launch)

Based on recent roll out of pricing program coupled with traditional seasonality, Q3 ‘23 product revenue has the potential to be around Q2 ‘23 levels